Marker Therapeutics, Inc. (MRKR )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MRKR
- Company Marker Therapeutics, Inc.
- Price $1.18
- Changes Percentage -15.71
- Change -0.22
- Day Low $1.13
- Day High $1.39
- Year High $5.99
- Year Low $1.13
- Market Cap $12,636,620
- Price Avg 50 EMA (D) $2.03
- Price Avg 200 EMA (D) $3.37
- Exchange NASDAQ
- Volume 157,846
- Average Volume 142,872
- Open $1.38
- Previous Close $1.4
- EPS -1.07
- PE -1.10
- Earnings Announcement 2025-03-24 10:59:00
- Shares Outstanding $10,709,000
Company brief: MARKER THERAPEUTICS, INC. (MRKR )
- Healthcare
- Biotechnology
- Dr. Juan F. Vera M.D.
- https://www.markertherapeutics.com
- US
- N/A
- 07-16-2002
- US57055L2060
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.